THE DESK
About this desk
An independent literature digest on two ageing-related peptides, organised around a distinction the rest of the category tends to collapse.
What this is
yolopeptide is an independent editorial digest of the published research on two peptides studied in ageing biology: epitalon and MOTS-c. It sells nothing, dispenses nothing, and has no clinical function. Its only product is a reading of a literature — twelve studies, summarised in plain language, with every figure attached to the source it came from.
The category it covers is unusually noisy. Longevity compounds attract confident claims because the promise is enormous and the evidence is slow, and the gap between the two is where most of the writing on this subject lives. A desk that reports what was measured, in which species, against which endpoint, is a modest corrective and the only one available without running new studies.
The organising line
Every page here is built on one distinction: lifespan is how long something lives, healthspan is how much of that life is spent in good function. Longevity marketing treats them as synonyms. The research does not, and the two compounds catalogued here happen to sit on opposite sides of the line — epitalon carrying the only survival-curve result on the desk, MOTS-c carrying the only functional-capacity data.
Holding the distinction open changes how a claim reads. A study that moves maximum lifespan without moving mean lifespan is a real result about the tail of a distribution and not a general claim about living longer. A study that measures grip strength in old mice is about function and makes no survival claim at all. A study that measures telomere length in cultured cells is about neither, and is the kind most often quoted as if it were about both.
How a claim earns a place here
Every substantive statement on this site traces to a numbered entry on the references page, and the numbers are not decorative — quantities, sample sizes, durations and effect sizes each carry the study they came from. Nothing is summarised from secondary reporting, and no claim is included because it is widely believed.
Where the record is thin, the page says so rather than filling the gap. Where community reports appear, they are labelled as anecdote, presented without any dose or schedule, and the reports of no effect are included alongside the reports of benefit, because leaving them out is how an uncontrolled impression gets promoted into a finding.
Where the evidence has a structural weakness, it is stated on the page rather than in a footnote. The clearest case is epitalon, whose foundational work comes largely from one research lineage; that fact belongs next to the findings, not underneath them.
What this desk will not do
It will not publish a human dose, a schedule, or a cycling protocol — for either compound, in any context, including in answer to a question that asks for one directly. No published human pharmacokinetic study exists for either peptide, so any such figure would be invented.
It will not offer medical advice or address a reader's individual situation, and it is not a substitute for a qualified clinician. It will not recommend a supplier, a source or a product, and it is not affiliated with one.
The name is a joke that the content does not repeat. Domains are cheap, evidence is not, and the editorial standard on these pages is set by the second of those facts.